Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?

Treatment of relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) has dramatically improved thanks to the development of mechanism-driven agents including drugs that inhibit kinases in the BCR pathway or BCL2. The treating physician has now the opportunity to decide i) which patient can be s...

Descripción completa

Detalles Bibliográficos
Autores principales: Cuneo, Antonio, Foà, Robin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Università Cattolica del Sacro Cuore 2019
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402553/
https://www.ncbi.nlm.nih.gov/pubmed/30858962
http://dx.doi.org/10.4084/MJHID.2019.024

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6402553/
https://www.ncbi.nlm.nih.gov/pubmed/30858962
http://dx.doi.org/10.4084/MJHID.2019.024

Ejemplares similares